Early pelvic prolapse diagnosis and treatment markers and their application

A technology of pelvic prolapse and molecular markers, applied in the field of early pelvic prolapse diagnosis and treatment markers, can solve problems such as unclear pathogenesis, and achieve clear results, strong selectivity, and strong specificity

Active Publication Date: 2018-01-12
GUAN BOJIAN BIOTECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although many studies have revealed factors related to the occurrence of POP, its specific pathogenesis is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Early pelvic prolapse diagnosis and treatment markers and their application
  • Early pelvic prolapse diagnosis and treatment markers and their application
  • Early pelvic prolapse diagnosis and treatment markers and their application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The collection of embodiment 1 case

[0038] From September 2012 to December 2013, a total of 9 POP patients who visited the Department of Obstetrics and Gynecology of Union Medical College Hospital were collected. A total of 3 cases were collected using age and place of residence as matching factors. The uterosacral ligament tissue samples of all subjects were obtained, numbered and stored in a -80°C low-temperature refrigerator.

[0039] Inclusion criteria for POP group: a. POP-Q score ≥ II degree after gynecological examination;

[0040] b. Continuously living in the Beijing area;

[0041] c. At least one childbirth history.

[0042] Exclusion criteria: a. Patients who received hormone replacement therapy in the past 3 months;

[0043] b. Patients with connective tissue diseases (rheumatoid arthritis, systemic lupus erythematosus, polymyositis, Marfan syndrome, Eydown syndrome);

[0044] c. Pregnant patients;

[0045] d. The patient refuses to join;

[0046] e...

Embodiment 2

[0058] Example 2 High-throughput sequencing and analysis

[0059] RNA extraction is performed on the tissue, followed by agarose gel electrophoresis after RNA extraction. From the results of electrophoresis, it can be preliminarily judged whether the quality of the extracted RNA sample is qualified or not, and whether it can be used for further transcriptome analysis. Then, the extraction of RNA samples was detected by NanoDrop1000 spectrophotometer, and the sample requirements for RNA-seq sequencing: OD260 / OD280 was 1.8-2.2.

[0060] The sequencing platform is the HiSeq 2500 high-throughput sequencing platform of Illumina, which performs high-throughput transcriptome deep sequencing. After sequencing, we use Fast-QC (http: / / www.bioinformatics.babraham.ac.uk / projects / fastqc / ) The software evaluates the quality of sequencing data as a whole, including base quality value distribution, quality value position distribution, GC content, PCR duplication content, kmer frequency, etc. ...

Embodiment 3

[0061] Example 3 ZCCHC12 and KCNG1 gene expression in pelvic prolapse patients and controls in uterosacral ligament tissue

[0062] 1. Materials and methods

[0063] 1. Materials

[0064] The uterosacral ligament tissues of 35 cases of pelvic prolapse patients and 5 cases of control uterosacral ligament tissues were selected and grouped and numbered. The control group was patients with benign gynecological diseases undergoing laparotomy or vaginal hysterectomy, pelvic organ prolapse was ruled out by vaginal examination, and no urinary incontinence symptoms. Of the 35 patients with pelvic prolapse, 17 were grade II, 8 were grade III, and 10 were grade IV.

[0065] 2. Method

[0066] 2.1 Extraction of total RNA from uterosacral ligament tissues of patients with pelvic prolapse and controls

[0067] use Reagent (invitrogen, Cat. No. 15596-018) was used to extract sample RNA, and the experimental operation was carried out according to the product manual. The specific operati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an early pelvic organ prolapse diagnosis and treatment marker and application thereof, in particular to application of a ZCCHC12 gene and/or KCNG1 gene to early pelvic organ prolapse diagnosis and treatment. The inventor performs gene screening through analysis by adopting a biological information method based on high-throughput sequencing results, selects out candidate genes ZCCHC12 gene and KCNG1 gene and further proves a relation between the candidate genes and the pelvic organ prolapse through a molecular cell biological method; the candidate genes have a very good correlation with the pelvic organ prolapse, the candidate genes are found to be obviously highly expressed at the early stage of the pelvic organ prolapse in combination with clinical staging, the marker can be used for preparing an auxiliary diagnosis and treatment preparation for early pelvic organ prolapse, and the clinical application value is important.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular to markers for the diagnosis and treatment of early pelvic cavity prolapse and its application, more specifically to the application of ZCCHC12 gene and / or KCNG1 gene in the diagnosis and treatment of early pelvic cavity prolapse. Background technique [0002] Pelvic organ prolapse (Pelvic organ prolapse, POP) is caused by the defect, damage or dysfunction of the pelvic floor support structure. It is a common disease that affects the quality of life of middle-aged and elderly women. and dysfunction. The clinical manifestations are prolapse of the uterus, vagina, bladder, urethra, colorectum, small intestine and other organs, often accompanied by symptoms such as urinary incontinence, urination and defecation disorders, and sexual dysfunction. Epidemiological studies have shown that up to 50% of adult women are troubled by this disease, and the incidence of both primary POP and re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/11C07K14/47C12Q1/68A61K48/00A61K31/7105A61P15/00G01N33/68G01N33/577
Inventor 杨承刚孙耀兰
Owner GUAN BOJIAN BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap